Array BioPharma (Nasdaq: ARRY) reported earnings on Feb. 2. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended Dec. 31 (Q2), Array BioPharma beat expectations on revenues and exceeded expectations on earnings per share.
Compared to the prior-year quarter, revenue increased significantly and GAAP loss per share dropped.
Margins increased across the board.
Revenue details
Array BioPharma reported revenue of $23.2 million. The eight analysts polled by S&P Capital IQ foresaw a top line of $21.8 million. Sales were 41% higher than the prior-year quarter's $16.5 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions.
EPS details
EPS came in at -$0.06. The seven earnings estimates compiled by S&P Capital IQ predicted -$0.12 per share. GAAP EPS were -$0.06 for Q2 against -$0.23 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Figures may be non-GAAP to maintain comparability with estimates.
Margin details
For the quarter, gross margin was 73.0%, 1,770 basis points better than the prior-year quarter. Operating margin was 0.1%, 5,630 basis points better than the prior-year quarter. Net margin was -16.4%, 5,900 basis points better than the prior-year quarter.
Looking ahead
Next quarter's average estimate for revenue is $19.0 million. On the bottom line, the average EPS estimate is -$0.17.
Next year's average estimate for revenue is $85.8 million. The average EPS estimate is -$0.46.
Investor sentiment
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 216 members out of 225 rating the stock outperform, and nine members rating it underperform. Among 71 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 69 give Array BioPharma a green thumbs-up, and two give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Array BioPharma is outperform, with an average price target of $4.50.
The biotechnology and health-care investing landscape is littered with also-rans and a few major winners. Is Array BioPharma the right stock for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company Fool co-founder David Gardner believes will be a phenomenal success over the next few years. Click here for instant access to this free report.
- Add Array BioPharma to My Watchlist.
